FDA Reviews Roche's Combination Therapy for Lymphoma Treatment

The U.S. FDA has accepted Roche's supplemental application for a combination of Lunsumio and Polivy to treat adult patients with relapsed or refractory large B-cell lymphoma. This submission is supported by Phase III study results demonstrating a significant reduction in disease progression or death. The FDA is expected to make a decision on this therapy by early 2027.